iVeena Delivery Systems

iVeena Delivery Systems, Inc. is a private clinical-stage ophthalmology company developing disease-modifying drug innovations for refractive disorders. iVeena has licensed its lead asset, IVMED-80, to Glaukos Corporation, an orphan drug designated eye drop for the treatment of keratoconus. iVeena is developing IVMED-85, a first-in-class investigational eye drop formulation for pediatric myopia.